No votes yet

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Patricia A. Mangan
Charise L. Gleason
Teresa Miceli
CJON 2013, 17(6), 43-47 DOI: 10.1188/13.CJON.43-47

When caring for patients with multiple myeloma, questions often arise about the role and timing of autologous hematopoietic stem cell transplantation. As a complement to the other articles in this supplement, as well as to ensure that readers are provided with the insight needed to feel comfortable speaking to patients and other practitioners about this topic, the authors address eight frequently asked questions about common decision points in the process of autologous hematopoietic stem cell transplantation as a treatment for patients with multiple myeloma.


Attal, M., Harousseau, J. L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J. G., … Bataille, R. (2003). Single versus double autologous stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine, 349</i>, 2495-2502. doi:10.1056/NEJMoa032290

Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J., Fuzibet, J. G., Rossi, J. F., … Bataille, R. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. <i>New England Journal of Medicine, 335</i>, 91-97. doi:10.1056/NEJM199607113350204

Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., … Harousseau, J. L. (2012). Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine, 366</i>, 1782-1791. doi:10.1056/NEJMoa1114138

Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D., Mills, G. M., … Salmon, S. E. (2002). Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. <i>Blood, 99</i>, 3136-3168. doi:10.1182/blood.V99.9.3163

Bladé, J., Rosiñol, L., Cibeira, M. T., Rovira, M., & Carreras, E. (2010). Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. <i>Blood, 115</i>, 3655-3663.

Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., … Lonial, S. (2011). International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood, 117</i>, 6063-6073. doi:10.1182/blood-2011-02-297325

Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q. L., Chen, C. I., … Keith Stewart, A. (2004). The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. <i>British Journal of Haematology, 125</i>, 64-68. doi:10.1111/j.1365-2141.2004.04867.x

Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S.E, Hawkins, K., … Selby, P. J. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. <i>New England Journal of Medicine, 348</i>, 1875-1883. doi:10.1056/NEJMoa022340

ClinicalTrials.gov. (n.d.a). Randomized study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone to high-dose treatment with ASCT in the initial management of myeloma in patients up to 65 years of age (IFM/DFCI 2009). Retrieved from <a target="_blank" href='http://clinicaltrials.gov/ct2/show/NCT01191060?term=01191060&rank=1'>htt...

ClinicalTrials.gov. (n.d.b). Stem cell transplant with lenalidomide maintenance in patients with multiple myeloma (BMT CTN 0702). Retrieved from <a target="_blank" href='http://clinicaltrials.gov/show/NCT01109004'>http://clinicaltrials.gov/sh...

Cook, G., Liakopoulou, E., Pearce, R., Cavet, J., Morgan, G. J., Kirkland, K., … Marks, D. I. (2011). Factors influencing the outcome of a second autologous stem cell transplant (AHSCT) in relapsed multiple myeloma: A study from the British Society of Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation, 17</i>, 1638-1645. doi:10.1016/j.bbmt.2011.04.005

Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., … Gore, M. (1998). A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. <i>British Journal of Haematology, 102</i>, 495-502. doi:10.1046/j.1365-2141.1998.00795.x

Fermand, J. P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., … Brouet, J. C. (1998). High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. <i>Blood, 92</i>, 3131-3136.

Gertz, M. A., Ghobrial, I., & Luc-Harousseau, J. (2009). Multiple myeloma: Biology, standard therapy, and transplant therapy. <i>Biology of Blood and Marrow Transplantation, 15</i>(Suppl.), S46-S52. doi:10.1016/j.bbmt.2008.10.006

Giralt, S., Landau, M., & Palumbo, A. (2012). Long-term myeloma care (maintenance and second primary malignancies). <i>HemOnc Today</i>, (Suppl. to Feb 2012), 11-13.

Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., … Durie, B. G. (2009). International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). <i>Leukemia, 23</i>, 1904-1912. doi:10.1038/leu.2009.127

Hari, P. N., & McCarthy, P. L. (2013). Multiple myeloma: Future directions in autologous transplantation and novel agents. <i>Biology of Blood and Marrow Transplantation, 19</i>(Suppl.), S20-S25. doi:10.1016/j.bbmt.2012.11.002

Mateos, M. V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A. I., López de la Guía, A., … San-Miguel, J. F. (2012). Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood, 120</i>, 2581-2588. doi:10.1182/blood-2012-05-427815

Matsui, W., Borrello, I., & Mitsiades, C. (2012). Autologous stem cell transplantation and multiple myeloma cancer stem cells. <i>Biology of Blood and Marrow Transplantation, 18</i>(Suppl.), S27-S32.

McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., … Linker, C. (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine, 366</i>, 1770-1781. doi:10.1056/NEJMoa1114083

Moreau, P., Avet-Loiseau, H., Harousseau, J. L., & Attal, M. (2011). Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. <i>Journal of Clinical Oncology, 29</i>, 1898-1906. doi:10.1200/JCO.2010.32.5878

Neben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., … Goldschmidt, H. (2010). Combining information regarding chromosomal aberrations t(4;14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. <i>Haematologica, 95</i>, 1150-1157. doi:10.3324/haematol.2009.016436

Olin, R. L., Vogl, D. T., Porter, D. L., Luger, S. M., Schuster, S. J., Tsai, D. E., … Stadtmauer, E. A. (2009). Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. <i>Bone Marrow Transplantation, 43</i>, 417-422. doi:10.1038/bmt.2008.334

Palumbo, A., & Anderson, K. (2011). Multiple myeloma. <i>New England Journal of Medicine, 364</i>, 1046-1060. doi:10.1056/NEJMra1011442

Palumbo, A., Attal, M., & Roussel, M. (2011). Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: Maintenance therapy and overall survival. <i>Clinical Cancer Research, 17</i>, 1253-1263. doi:10.1158/1078-0432.CCR-10-1925

Palumbo, A., Cavallo, F., Hardan, I., Lupo, B., Redogila, V., Levin, M., … Boccadoro, M. (2011). Melphalan/prednisone/lenidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200)in newly diagnosed multiple myeloma (MM) patients <65 years: Results of a randomized phase III study. Retrieved from <a target="_blank" href='http://ash.confex.com/ash/2011/webprogram/Paper36073.html'>http://ash.co...

Palumbo, A., & Rajkumar, S. V. (2010). Multiple myeloma: Chemotherapy or transplantation in the era of new drugs. <i>European Journal of Haematology, 84</i>, 379-390. doi:10.1111/j.1600-0609.2010.01431.x

Pasquini, M. C., & Wang, Z. (2012). Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2012. Retrieved from <a target="_blank" href='http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Docume...

Sonneveld, P., Schmidt-Wolf, I. G., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., … Goldschmidt, H. M. (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. <i>Journal of Clinical Oncology, 30</i>, 2946-2955. doi:10.1200/JCO.2011.39.6820